- Home
- WNW vs ALZN Comparison
WNW vs ALZN Comparison
Compare WNW & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WNW | ALZN |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3M | 3.9M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | WNW | ALZN |
|---|---|---|
| Price | $4.64 | $1.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | ★ 2.3M | 34.1K |
| Earning Date | 05-12-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.99 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.14 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.05 | $0.84 |
| 52 Week High | $13.52 | $8.22 |
Technical Indicators
Market Signals| Indicator | WNW | ALZN |
|---|---|---|
| Relative Strength Index (RSI) | 61.31 | 59.62 |
| Support Level | $1.37 | $1.03 |
| Resistance Level | $5.56 | $2.54 |
| Average True Range (ATR) | 0.76 | 0.06 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 58.51 | 94.48 |
Price Performance
Historical ComparisonAbout WNW Meiwu Technology Company Limited
Meiwu Technology Co Ltd operates as an online food retail store and franchise restaurants in China. The products offered include green food, organic food, intangible cultural heritage food products, agricultural products bearing geographical indications, and pollution-free products. It operates in three segments including Clean Food platform, Skincare products & service and Technical Service. The company generates the majority of its revenue from Technical services.
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.